Comment on "Locoregional Failure During and After Short-Course Radiotherapy Followed by Chemotherapy and Surgery Compared to Long-Course Chemoradiotherapy and Surgery: A Five-Year Follow-Up of the RAPIDO Trial": The RAPIDO Trial Does Not Achieve Its Primary Endpoint

Affiliations

¹ From the University Federation of Radiation Oncology of Mediterranean Occitanie, Montpellier Cancer Institute (ICM), Univ Montpellier, INSERM U1194 IRCM, Montpellier, France.
² Biometrics Unit ICM, Montpellier Cancer Institute, Univ Montpellier, Montpellier, France.
³ Institut de Cancérologie de Lorraine, APEMAC, Université de Lorraine, Nancy, France.

Comment

Olivier Riou et al. Ann Surg Open. 2023.

. 2023 Jun 2;4(2):e288.

doi: 10.1097/AS9.0000000000000288. eCollection 2023 Jun.

¹ From the University Federation of Radiation Oncology of Mediterranean Occitanie, Montpellier Cancer Institute (ICM), Univ Montpellier, INSERM U1194 IRCM, Montpellier, France.
² Biometrics Unit ICM, Montpellier Cancer Institute, Univ Montpellier, Montpellier, France.
³ Institut de Cancérologie de Lorraine, APEMAC, Université de Lorraine, Nancy, France.

No abstract available

Comment on

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial.
Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Putter H, Berglund Å, Cervantes A, Crolla RMPH, Hendriks MP, Capdevila J, Edhemovic I, Marijnen CAM, van de Velde CJH, Glimelius B, van Etten B; Collaborative Investigators. Dijkstra EA, et al. Ann Surg. 2023 Oct 1;278(4):e766-e772. doi: 10.1097/SLA.0000000000005799. Epub 2023 Jan 20. Ann Surg. 2023. PMID: 36661037 Free PMC article. Clinical Trial.

1. Dijkstra EA, Nilsson PJ, Hospers GAP, et al. . Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery—a five-year follow-up of the RAPIDO trial [published online ahead of print January 20, 2023]. Ann Surg. doi: 10.1097/SLA.0000000000005799. - PMC - PubMed
1. Conroy T, Bosset J-F, Etienne P-L, et al. ; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–715. - PubMed
1. Brenner DJ, Hlatky LR, Hahnfeldt PJ, et al. . The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. Radiat Res. 1998;150:83–91. - PubMed
1. Suwinski R, Wzietek I, Tarnawski R, et al. . Moderately low alpha/beta ratio for rectal cancer may best explain the outcome of three fractionation schedules of preoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:793–799. - PubMed
1. Glynne-Jones R, Hollingshead J. TNT and local recurrence in the RAPIDO trial—untangling the puzzle [published online ahead of print March 2, 2023]. Nat Rev Clin Oncol. doi: 10.1038/s41571-023-00751-4. - PubMed